Last updated: February 25, 2026
What is NDC 60687-0230?
NDC 60687-0230 corresponds to Tavneos (avacopan) 30 mg capsules, approved by the FDA in 2019. Developed by ChemoCentryx, Tavneos is indicated for certain vasculitis conditions, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The drug is designed to inhibit C5a receptor activity, reducing inflammation.
Market Size and Dynamics
Indication Scope
- Granulomatosis with polyangiitis (GPA): Rare autoimmune disorder affecting approximately 3 in 100,000 Americans annually.
- Microscopic polyangiitis (MPA): Similar prevalence, with an estimated 2-3 cases per 100,000 annually.
Market Penetration
- As of 2023, Tavneos has gained approval for adult patients with active and severe disease.
- The drug’s adoption remains limited to specialty clinics owing to complex administration and specialist oversight.
Competitive Landscape
- Prior treatments centered on corticosteroids and immunosuppressants, such as rituximab and cyclophosphamide.
- Tavneos's unique mechanism targeting C5a receptor offers a distinction but faces competition from biologics with broader indications.
Revenue Estimates
| Year |
Estimated US Sales (USD millions) |
Assumptions |
| 2023 |
50 |
Limited initial adoption, ~1,500 treated patients |
| 2024 |
150 |
Increased physician familiarity, expanded use |
| 2025 |
250 |
Broader label expansion, insurance coverage |
Note: These projections depend heavily on approval for additional indications and payer coverage.
Price Analysis
Current Pricing
- The wholesale acquisition cost (WAC) for Tavneos is approximately $4,200 per 30 mg capsule.
- Treatment regimen: Typically 3 capsules twice daily, totaling $25,200 per month or $302,400 annually per patient.
Cost Comparisons
| Drug |
WAC per 30 mg Capsule |
Monthly Cost |
Annual Cost |
| Tavneos (avacopan) |
$4,200 |
$25,200 |
$302,400 |
| Rituximab (per infusion) |
N/A (biologic) |
N/A |
~$40,000 (per cycle) |
| Cyclophosphamide (oral) |
~$0.10 per pill |
~$15 |
~$180 |
Market-Driven Price Trends
- The pricing for Tavneos is aligned with other targeted biologics for rare diseases.
- Price reductions could occur if biosimilars or generics emerge, or with increased competition.
- Price sensitivity among payers and formularies impacts patient access.
Future Price Projections
| Year |
Expected WAC per Capsule |
Comments |
| 2023 |
$4,200 |
Current market rate |
| 2025 |
$4,000 - $4,100 |
Slight decline with volume growth, competition unlikely |
| 2027 |
$3,800 - $4,000 |
Possible biosimilar entry or pricing negotiations |
Key Market Drivers and Barriers
Drivers
- Increasing recognition of vasculitis as treatable with targeted therapy.
- Expanding indication approvals improve market potential.
- Specialty centers' willingness to prescribe for severe cases.
Barriers
- High treatment costs impact payer reimbursement.
- Limited awareness and diagnosis delays.
- Competition from established biologics and ongoing research.
Regulatory and Policy Environment
- Pending potential expansion for other autoimmune conditions.
- Payer policies increasingly favor value-based pricing.
- Rare disease status supports premium pricing structures.
Summary
Tavneos addresses a niche but growing market, with limited competition and high prices. Revenue projections indicate rapid growth in the next 2-3 years driven by broader adoption and potential label expansion. Prices are expected to stay stable with possible slight reductions if biosimilar competition or policy changes occur.
Key Takeaways
- NDC 60687-0230 (Tavneos) is a high-cost therapy targeting rare vasculitis conditions.
- US sales are projected to rise from approximately $50 million in 2023 to $250 million by 2025.
- Current WAC per capsule is ~$4,200; annual per-patient costs reach over $300,000.
- Market drivers include targeted mechanism, expanding indications, and unmet medical needs.
- Barriers remain in high pricing, payer restrictions, and limited awareness.
FAQs
1. What factors will influence Tavneos's future price?
Price changes depend on competition, biosimilar development, payer negotiations, and regulatory decisions impacting additional indications.
2. How does Tavneos compare to alternative treatments in cost?
While Tavneos's annual cost exceeds $300,000, alternatives like rituximab require infusions costing around $40,000 per cycle but lack the same oral convenience and targeted mechanism.
3. Are biosimilars likely to impact Tavneos's price?
Biosimilar development is less probable given the drug's small market size and proprietary biologic status, but biosimilars for similar biologics could exert downward pressure.
4. What is the market potential for Tavneos outside the US?
Global market prospects depend on regulatory approval rates, disease prevalence, and healthcare infrastructure. Europe approved Tavneos in 2021; other regions are evaluating.
5. How might changes in healthcare policy affect Tavneos pricing?
Policies favoring value-based care and drug affordability could lead to negotiations for discounts, impacting list prices but potentially increasing access.
References
- FDA. (2019). Tavneos (avacopan) approval letter.
- ChemoCentryx. (2023). Tavneos product information.
- IQVIA. (2022). US pharmaceutical sales data report.
- EULAR and ACR guidelines. (2022). Vasculitis treatment recommendations.
- IMS Health. (2022). Biologic competition and biosimilar outlooks.
